<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

HT-29

Description

HT-29 (Colorectal Cancer CDX Model) 

The HT-29 colorectal cancer cell line was derived from a human colon adenocarcinoma. It carries a BRAF V600E mutation, a common driver mutation in colorectal cancer. HT-29 is one of the most frequently used colon cancer models in preclinical pipelines. Its reproducibility makes it valuable for translational research. 

Key Features: 

  • Derived from colon adenocarcinoma. 
  • BRAF V600E mutation. 
  • Epithelial morphology with glandular features. 
  • Robust xenograft formation. 

Applications: 
HT-29 is applied in studies of BRAF-targeted therapies for colorectal cancer. It supports biomarker identification and mechanism-of-action research. Researchers use it to evaluate resistance pathways to chemotherapy. Its genetic stability makes it a benchmark colon cancer model.

Details
Tumor Type
Colorectal
Tumor Subtype
Colorectal Adenocarcinoma
Organism
Human
Mouse Sex
Female
Mouse Strain
Athymic Nude
Mutated Genes
APC
Mutation: p.E853Ter
Effect: Stop-Gain
Impact: Pathogenic
Mutation: p.T1556NfsTer3
Effect: Frameshift Variant
Impact: Pathogenic
BRAF
Mutation: p.V600E
Effect: Missense Variant
Impact: Pathogenic & Likely Pathogenic & Not Provided
PIK3CA
Mutation: p.P449T
Effect: Missense Variant
Impact: Pathogenic / Likely Pathogenic
SMAD4
Mutation: p.Q311Ter
Effect: Stop-Gain
Impact: Pathogenic
TP53
Mutation: p.R273H
Effect: Missense Variant
Impact: Pathogenic / Likely Pathogenic & Pathogenic & Likely Pathogenic
Lumin Data
Proteomics RNASeq WES
Expression Data
Growth Curve
View on Lumin